ProPhase focuses on three primary areas: molecular diagnostics and precision oncology including the BE-Smart Esophageal Cancer Test, genomics through Nebula Genomics, and consumer health via OTC dietary supplements. In December 2025, ProPhase announced a non-binding Letter of Intent for a proposed reverse merger with Advanced Biological Laboratories S.A., though the transaction is preliminary and subject to due diligence and regulatory approvals.
Cyborg Score Rationale
The company reported operating income of -$38.6M, and transitioned from Nasdaq to the OTC market in January 2026. While the company has diverse product portfolios and strategic initiatives, execution risks and financial challenges limit near-term prospects.
Top Insights
Company transitioned from Nasdaq to OTC market in January 2026
Proposed reverse merger with Advanced Biological Laboratories S.A. announced in December 2025
BE-Smart is an 8-protein mass-spectrometry-based proteomic assay for patients with Barrett's Esophagus
Operates consumer supplement brands including Legendz XL for male sexual enhancement and Triple Edge XL for energy
Named Competitors
Quest Diagnostics — Major clinical laboratory testing and diagnostic services provider
Laboratory Developed Test (LDT) Competitors — Multiple diagnostic firms developing esophageal cancer and Barrett's esophagus screening tests
Direct-to-Consumer Supplement Brands — Various OTC dietary supplement manufacturers competing in male enhancement and energy categories
Recent Developments
(January 2026) Transition from NASDAQ to OTC market
(December 2025) Non-binding Letter of Intent for proposed reverse merger with Advanced Biological Laboratories S.A.
(Late 2025) Stockholders approved and implemented 1-for-10 reverse stock split
Open the full interactive ProPhase Labs, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.